Health Canada approves Bimzelx (bimekizumab injection) for the treatment of adults with axial spondyloarthritis (axSpA).- UCB
UCB Canada Inc. is pleased to announce that Bimzelx (bimekizumab injection) has received authorization from Health Canada for two new indications. On February 23, 2024, BImzelx was approved for the treatment of adults with active psoriatic arthritis (PsA) and on March 11, 2024, the therapy also received approval for the treatment of adults with axial spondyloarthritis (axSpA) .